PubMed Health⌕ Search

PubMed · 15845752

Electroconvulsive therapy: a selected review.

Abstract

Since its introduction in 1938, electroconvulsive therapy (ECT) has remained an important treatment for selected serious neuropsychiatric illnesses and continues to be one of the most effective treatments in psychiatry. ECT has evolved into a technically sophisticated procedure with a proven track record of safety. For this review, the authors relied heavily on the database from the APA Task Force Report on ECT (2001), updated with additional searches of computerized literature databases for the period 1999-2003. The review is necessarily a selective one, given the exponential growth of literature in the field. The authors attempt to summarize key areas of ECT practice, informed by relevant research findings and expert consensus when applicable. The authors also point out areas of controversy and gaps in our present knowledge. Although this review summarizes the scientific literature about the use of ECT generally, emphasis is given to describing literature pertaining to the treatment of geriatric patients when such information is available or when older patients or the disorders from which they suffer merit special consideration.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Robert M Greenberg, Charles H Kellner. 2005. Electroconvulsive therapy: a selected review.. https://doi.org/10.1176/appi.ajgp.13.4.268

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗